ArticleBiomedical engineering online2025
Conductivity-based choline contrast as a potential imaging biomarker for assessing abnormal choline metabolism.
Article in Biomedical engineering online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAbnormal brain metabolite levels are indicators of physiological and pathological tissue conditions. Noninvasive imaging of these metabolites enables functional assessment of tissue in situ. One consistent hallmark of various cancers is altered choline metabolism. Magnetic resonance (MR)-based conductivity imaging method provides novel tissue contrast by reflecting the concentration and mobility of constituent ions. This study presents preliminary evidence supporting the use of electrical conductivity of choline as a potential imaging biomarker for assessing abnormal choline metabolism.
methodsIn vitro measurements evaluated changes in conductivity corresponding to variations in brain metabolite concentrations, measurable by MRI. Phantom imaging compared the sensitivity of conductivity imaging with MRSI to validate these results. To further assess sensitivity, a choline solution at twice the normal concentration was directly injected into the mouse brain, followed by an imaging experiment. Finally, in vivo imaging was performed using a mouse brain tumor model to compare choline-related conductivity contrasts between normal and cancerous tissues.
resultsIn vitro measurements showed metabolite-dependent conductivity, with Cho and ACh showing linear concentration-dependent increases, while NAA and Lac exhibited modest changes, Glx showed weak changes, and Cr and mI showed little to no changes. Phantom conductivity imaging provided linear sensitivity across physiologically relevant concentrations and maintained accuracy even in choline-dominant mixture phantoms, in contrast to MRSI, which underestimated Cho at low levels. In vivo focal choline injection and tumor models both exhibited marked conductivity increases of more than 20% and 150%, respectively, compared to the contralateral normal region.
conclusionElectrical conductivity imaging can more sensitively detect choline concentrations associated with abnormal metabolism and may serve not only as a complementary imaging method but also as a potential quantitative biomarker for cancer diagnosis and metabolic assessment in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.